NCT02964637 · RECRUITING
Diagnosing Frontotemporal Lobar Degeneration
This is an observational study, meaning no drug or treatment is given. Researchers are working to build better diagnostic tools, such as brain imaging and cognitive testing, to accurately identify frontotemporal dementia and related conditions like PSP and corticobasal syndrome. No phase is listed because it is not a treatment trial.
You may qualify if
- Participant must have a reliable study partner who can provide an independent evaluation of functioning.
- Able to read, understand and speak English for neuropsychological testing.
- All subjects must meet one of these diagnostic criteria (A) probable behavioral variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic variant PPA and [18F]T807 negative (D) probable CBS: using current criteria for CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy (NINDS-SPSP) (F) FTD-MND
- Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and MMSE score equal to or greater than 28
You're excluded if
- Patients with clinical, imaging or CSF A beta/ tau profile consistent with AD
- History of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded.
- Premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from PET study.
- Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-03-30